ALK-Abelló A/S
ALK-B
Peringkat dalam Saham
#2325
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Harga Saham
$38.39
Kapitalisasi Pasar
$8.52B
Perubahan (1 hari)
1.68%
Perubahan (1 tahun)
16.26%
Negara
DK
Perdagangan ALK-Abelló A/S (ALK-B)
Kategori
Healthcare
Rasio P/E untuk ALK-Abelló A/S (ALK-B)
Rasio P/E per October 2026 TTM: 37.05
Menurut laporan keuangan dan harga saham terbaru dari ALK-Abelló A/S, rasio P/E saat ini (TTM) adalah 37.05. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar 46.05.
Riwayat rasio P/E untuk ALK-Abelló A/S dari 2004 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 37.05 | -14.24% |
| 2024 | 43.20 | -6.18% |
| 2023 | 46.05 | -27.16% |
| 2022 | 63.22 | -63.20% |
| 2021 | 171.81 | -84.26% |
| 2020 | 1.09K | -406.25% |
| 2019 | -356.45 | 453.21% |
| 2018 | -64.43 | 37.36% |
| 2017 | -46.91 | -240.23% |
| 2016 | 33.45 | 35.35% |
| 2015 | 24.71 | -28.87% |
| 2014 | 34.74 | -64.27% |
| 2013 | 97.23 | 431.16% |
| 2012 | 18.31 | 15.24% |
| 2011 | 15.89 | -36.21% |
| 2010 | 24.90 | -27.76% |
| 2009 | 34.47 | -36.99% |
| 2008 | 54.70 | 49.95% |
| 2007 | 36.48 | -88.67% |
| 2006 | 321.97 | 14,387.47% |
| 2005 | 2.22 | -95.91% |
| 2004 | 54.30 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -22.31% |
US
|
|
| -28.36 | -176.54% |
US
|
|
| -24.57 | -166.31% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -18.14% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.